Foghorn Therapeutics Inc.
General ticker "FHTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $309.1M (TTM average)
Foghorn Therapeutics Inc. follows the US Stock Market performance with the rate: 19.0%.
Estimated limits based on current volatility of 4.5%: low 3.81$, high 4.17$
Factors to consider:
- Total employees count: 112 (-3.4%) as of 2024
- Top business risk factors: Operational and conduct risks, Key executive dependency, Limited operating history, Geopolitical risks, Product development risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.39$, 8.73$]
- 2026-12-31 to 2027-12-31 estimated range: [3.22$, 8.31$]
Financial Metrics affecting the FHTX estimates:
- Positive: with PPE of -4.5 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -25.92 <= 0.02
- Negative: negative Operating income
- Negative: Shareholder equity ratio, % of -54.77 <= 19.44
- Positive: Investing cash flow per share per price, % of 33.72 > -0.63
- Negative: negative Net income
Short-term FHTX quotes
Long-term FHTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $34.16MM | $22.60MM | $30.91MM |
| Operating Expenses | $142.06MM | $125.28MM | $113.02MM |
| Operating Income | $-107.91MM | $-102.68MM | $-82.11MM |
| Non-Operating Income | $13.71MM | $16.06MM | $7.82MM |
| R&D Expense | $109.69MM | $94.53MM | $85.47MM |
| Income(Loss) | $-94.20MM | $-86.62MM | $-74.28MM |
| Taxes | $4.23MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-98.43MM | $-86.62MM | $-74.28MM |
| Stockholders Equity | $-77.19MM | $-45.53MM | $-108.50MM |
| Assets | $285.92MM | $283.98MM | $198.10MM |
| Operating Cash Flow | $-118.11MM | $-100.41MM | $-86.10MM |
| Capital expenditure | $1.22MM | $0.91MM | $0.05MM |
| Investing Cash Flow | $144.45MM | $-29.90MM | $112.04MM |
| Financing Cash Flow | $1.78MM | $105.43MM | $1.02MM |
| Earnings Per Share** | $-2.34 | $-1.58 | $-1.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.